A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Summary

The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.

Timeline

Start

2010-11

Primary completion

2015-05

Completion

2015-05

Outcome

Missed primary endpoint

Stopped: “Study was stopped early due to lack of efficacy signal and safety concerns”

release “addition of IMGN901 to etoposide/carboplatin (E/C) was unlikely to demonstrate a sufficient improvement in progression-free survival compared to E/C alone” abbvie.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lorvotuzumab Mertansine	Monoclonal antibody	—	—
Comparator	Carboplatin	Small molecule	—	—
Comparator	Etoposide	Small molecule	—	—

Indications